ICON Public Limited Company (ICLR)
USD 204.4
(0.56%)
USD 204.4
(0.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.63 Billion USD | 17.26% |
| 2022 | 1.41 Billion USD | 55.71% |
| 2021 | 739.42 Million USD | 88.89% |
| 2020 | 488.83 Million USD | -1.23% |
| 2019 | 532.18 Million USD | 10.73% |
| 2018 | 451.76 Million USD | 31.49% |
| 2017 | 401.93 Million USD | -12.3% |
| 2016 | 379.42 Million USD | 14.26% |
| 2015 | 339.21 Million USD | 24.49% |
| 2014 | 263.68 Million USD | 46.7% |
| 2013 | 168.66 Million USD | 63.66% |
| 2012 | 111.09 Million USD | 29.33% |
| 2011 | 69.31 Million USD | -30.33% |
| 2010 | 127.72 Million USD | -10.57% |
| 2009 | 140.86 Million USD | 8.26% |
| 2008 | 130.11 Million USD | 47.44% |
| 2007 | 88.25 Million USD | 40.6% |
| 2006 | 62.76 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 31.93 Million USD | 41.32% |
| 2003 | 45.55 Million USD | 33.02% |
| 2002 | 32.23 Million USD | 50.98% |
| 2001 | 24.23 Million USD | 23.55% |
| 2000 | 16.05 Million USD | 52.85% |
| 1999 | 8.5 Million USD | -79.81% |
| 1998 | 42.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 380.89 Million USD | -13.43% |
| 2024 Q2 | 439.99 Million USD | -2.9% |
| 2024 Q1 | 453.14 Million USD | 6.72% |
| 2023 Q1 | 384.09 Million USD | 8.14% |
| 2023 FY | - USD | 17.26% |
| 2023 Q4 | 432.52 Million USD | 2.48% |
| 2023 Q2 | 403.85 Million USD | 5.14% |
| 2023 Q3 | 422.04 Million USD | 4.51% |
| 2022 FY | - USD | 55.71% |
| 2022 Q1 | 328.16 Million USD | 0.92% |
| 2022 Q2 | 353.34 Million USD | 7.67% |
| 2022 Q3 | 401.23 Million USD | 13.55% |
| 2022 Q4 | 355.18 Million USD | -11.48% |
| 2021 FY | - USD | 88.89% |
| 2021 Q1 | 133.41 Million USD | -2.62% |
| 2021 Q4 | 325.18 Million USD | 7.76% |
| 2021 Q3 | 301.75 Million USD | 131.52% |
| 2021 Q2 | 130.33 Million USD | -2.31% |
| 2020 Q4 | 137 Million USD | 9.19% |
| 2020 Q3 | 125.47 Million USD | 37.37% |
| 2020 FY | - USD | -1.23% |
| 2020 Q2 | 91.33 Million USD | -26.59% |
| 2020 Q1 | 124.42 Million USD | -5.05% |
| 2019 Q2 | 130.65 Million USD | 3.18% |
| 2019 Q1 | 126.63 Million USD | 8.52% |
| 2019 Q3 | 134.87 Million USD | 3.23% |
| 2019 FY | - USD | 10.73% |
| 2019 Q4 | 131.03 Million USD | -2.85% |
| 2018 Q2 | 112.46 Million USD | 2.76% |
| 2018 FY | - USD | 31.49% |
| 2018 Q3 | 116.31 Million USD | 3.42% |
| 2018 Q4 | 116.69 Million USD | 0.33% |
| 2018 Q1 | 109.44 Million USD | 3.33% |
| 2017 Q3 | 101.85 Million USD | 1.12% |
| 2017 Q2 | 100.72 Million USD | 0.06% |
| 2017 Q1 | 100.66 Million USD | 0.56% |
| 2017 FY | - USD | -12.3% |
| 2017 Q4 | 105.91 Million USD | 3.99% |
| 2016 Q4 | 100.09 Million USD | 4.07% |
| 2016 Q3 | 96.18 Million USD | 3.61% |
| 2016 Q1 | 91.46 Million USD | 1.08% |
| 2016 FY | - USD | 14.26% |
| 2016 Q2 | 92.83 Million USD | 1.5% |
| 2015 Q1 | 80.87 Million USD | -3.22% |
| 2015 Q3 | 86.28 Million USD | 4.47% |
| 2015 FY | - USD | 24.49% |
| 2015 Q4 | 90.48 Million USD | 4.87% |
| 2015 Q2 | 82.59 Million USD | 2.13% |
| 2014 Q1 | 54.89 Million USD | 8.33% |
| 2014 FY | - USD | 46.7% |
| 2014 Q4 | 83.56 Million USD | 13.81% |
| 2014 Q2 | 61.46 Million USD | 11.98% |
| 2014 Q3 | 73.42 Million USD | 19.45% |
| 2013 Q4 | 50.67 Million USD | 12.71% |
| 2013 Q3 | 44.95 Million USD | 5.26% |
| 2013 Q2 | 42.71 Million USD | 9.4% |
| 2013 FY | - USD | 63.66% |
| 2013 Q1 | 39.04 Million USD | 10.87% |
| 2012 Q1 | 22.91 Million USD | 31.96% |
| 2012 Q2 | 27.78 Million USD | 21.26% |
| 2012 Q3 | 31.72 Million USD | 14.18% |
| 2012 Q4 | 35.21 Million USD | 11.01% |
| 2012 FY | - USD | 29.33% |
| 2011 Q2 | 25.12 Million USD | -0.19% |
| 2011 Q4 | 17.36 Million USD | 55.33% |
| 2011 Q3 | 11.17 Million USD | -55.52% |
| 2011 FY | - USD | -30.33% |
| 2011 Q1 | 25.17 Million USD | -19.97% |
| 2010 Q3 | 26.17 Million USD | -23.84% |
| 2010 Q2 | 34.36 Million USD | -3.84% |
| 2010 Q1 | 35.73 Million USD | -8.66% |
| 2010 FY | - USD | -10.57% |
| 2010 Q4 | 31.46 Million USD | 20.21% |
| 2009 Q4 | 39.12 Million USD | 0.68% |
| 2009 Q1 | 34.89 Million USD | -4.14% |
| 2009 FY | - USD | 8.26% |
| 2009 Q3 | 38.85 Million USD | 5.47% |
| 2009 Q2 | 36.84 Million USD | 5.59% |
| 2008 Q1 | 27.61 Million USD | 108.47% |
| 2008 FY | - USD | 47.44% |
| 2008 Q4 | 36.39 Million USD | 3.79% |
| 2008 Q3 | 35.06 Million USD | 12.89% |
| 2008 Q2 | 31.06 Million USD | 12.52% |
| 2007 Q3 | 23.72 Million USD | 15.83% |
| 2007 FY | - USD | 40.6% |
| 2007 Q1 | 18.84 Million USD | 6.23% |
| 2007 Q4 | -325.97 Million USD | -1474.08% |
| 2007 Q2 | 20.48 Million USD | 8.66% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | 16.48 Million USD | 9.72% |
| 2006 Q4 | 17.74 Million USD | 7.62% |
| 2006 Q1 | 13.51 Million USD | 7.86% |
| 2006 Q2 | 15.02 Million USD | 11.21% |
| 2005 Q4 | 12.52 Million USD | 6.14% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | 9.46 Million USD | -8.17% |
| 2005 Q2 | 10.9 Million USD | 15.2% |
| 2005 Q3 | 11.8 Million USD | 8.28% |
| 2004 FY | - USD | 41.32% |
| 2004 Q2 | 12.59 Million USD | 8.09% |
| 2004 Q3 | 12.54 Million USD | -0.38% |
| 2004 Q4 | 10.3 Million USD | -17.88% |
| 2004 Q1 | 11.65 Million USD | 5.01% |
| 2003 Q1 | 8.05 Million USD | 2.34% |
| 2003 FY | - USD | 33.02% |
| 2003 Q4 | 11.09 Million USD | 8.67% |
| 2003 Q3 | 10.21 Million USD | 7.29% |
| 2003 Q2 | 9.51 Million USD | 18.15% |
| 2002 Q4 | 7.87 Million USD | 15.9% |
| 2002 FY | - USD | 50.98% |
| 2002 Q2 | 6.73 Million USD | 9.07% |
| 2002 Q1 | 6.17 Million USD | 5.84% |
| 2002 Q3 | 6.79 Million USD | 0.82% |
| 2001 Q3 | 5.55 Million USD | 410.2% |
| 2001 Q1 | 5.36 Million USD | 43.05% |
| 2001 Q4 | 5.83 Million USD | 5.12% |
| 2001 Q2 | 1.08 Million USD | -79.71% |
| 2001 FY | - USD | 23.55% |
| 2000 Q3 | 3.49 Million USD | 5.21% |
| 2000 Q4 | 3.74 Million USD | 7.27% |
| 2000 Q2 | 3.32 Million USD | -30.44% |
| 2000 Q1 | 3.15 Million USD | 91.04% |
| 2000 FY | - USD | 52.85% |
| 1999 Q4 | 2.5 Million USD | 13.64% |
| 1999 FY | - USD | -79.81% |
| 1999 Q2 | -34.8 Million USD | -336.73% |
| 1999 Q1 | 14.7 Million USD | 7.3% |
| 1999 Q3 | 2.2 Million USD | 106.32% |
| 1998 Q4 | 13.7 Million USD | 7.03% |
| 1998 Q2 | 12.1 Million USD | 21.0% |
| 1998 Q1 | 10 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q3 | 12.8 Million USD | 5.79% |
| 1997 Q4 | 10 Million USD | 0.0% |
| 1997 Q3 | 10 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 863.875% |
| Prenetics Global Limited | -47.89 Million USD | 3506.682% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 96820.095% |
| CareDx, Inc | -89.65 Million USD | 1919.9% |
| Exact Sciences Corporation | 41.87 Million USD | -3796.428% |
| Exagen Inc. | -19.15 Million USD | 8619.125% |
| Inotiv, Inc. | -26.5 Million USD | 6255.844% |
| Guardant Health, Inc. | -433.3 Million USD | 476.563% |
| Biodesix, Inc. | -37.1 Million USD | 4497.671% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 65756.43% |
| Precipio, Inc. | -4.31 Million USD | 37887.587% |
| iSpecimen Inc. | -9.1 Million USD | 18023.091% |
| Natera, Inc. | -383.27 Million USD | 525.716% |
| Aspira Women's Health Inc. | -16.49 Million USD | 9994.294% |
| Standard BioTools Inc. | -54.45 Million USD | 3096.25% |
| 23andMe Holding Co. | -291.87 Million USD | 659.032% |
| Castle Biosciences, Inc. | -45.02 Million USD | 3723.996% |
| Personalis, Inc. | -96.8 Million USD | 1785.486% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 1487.886% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 17112.418% |
| OpGen, Inc. | -29.51 Million USD | 5629.016% |
| T2 Biosystems, Inc. | -43.87 Million USD | 3818.901% |
| Myriad Genetics, Inc. | -67.8 Million USD | 2506.59% |
| NeoGenomics, Inc. | -17.6 Million USD | 9367.155% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 96820.095% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | -34.0% |
| RadNet, Inc. | 292.78 Million USD | -457.29% |
| MDxHealth SA | -30.46 Million USD | 5455.35% |
| Psychemedics Corporation | -251 Thousand USD | 650166.932% |
| Illumina, Inc. | -608 Million USD | 368.366% |
| Check-Cap Ltd. | -17.64 Million USD | 9345.102% |
| Twist Bioscience Corporation | -176.7 Million USD | 1023.385% |
| DarioHealth Corp. | -53.49 Million USD | 3150.189% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 3605.044% |
| Sera Prognostics, Inc. | -35.28 Million USD | 4723.992% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 16775.531% |
| OPKO Health, Inc. | -65.51 Million USD | 2590.488% |
| Medpace Holdings, Inc. | 363.15 Million USD | -349.306% |
| Neogen Corporation | 182.59 Million USD | -793.59% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 18619.149% |
| Prenetics Global Limited | -47.89 Million USD | 3506.682% |
| Mainz Biomed B.V. | -25.01 Million USD | 6623.748% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 21486.85% |
| Trinity Biotech plc | -24.09 Million USD | 6870.969% |
| Neuronetics, Inc. | -22.75 Million USD | 7269.331% |
| Sotera Health Company | 514.14 Million USD | -217.357% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 21486.85% |